CNN reported on March 5 that the new crown vaccine produced by Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd. will undergo phase 3 clinical trials with as many as 4000 participants in Bandung and Jakarta. The vaccine will be approved for emergency use in Indonesia as early as September.
Gao Fu, Academician of Institute of Microbiology, Chinese Academy of Sciences.
–
According to reports, this vaccine is a new coronavirus “recombinant protein subunit” vaccine jointly developed by the team of Academician Gao Fu from the Institute of Microbiology of the Chinese Academy of Sciences, and Chongqing Zhifei Longkoma Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of Chongqing Zhifei Biology. Intellectual property rights. This is the fifth Chinese-made new coronavirus vaccine approved for marketing by a foreign country.
Vaccine production workshop of Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
–
According to the report, Ridwan Kamil, the governor of West Java Province, Indonesia, supported researchers to conduct phase 3 clinical trials of the new crown vaccine developed by Anhui Zhifeilongkoma Company. He also encouraged the public to actively join the team of vaccine volunteers.
“In Indonesia, the Phase 3 clinical trial of the new crown vaccine developed by Anhui Zhifeilongkoma Company requires 4,000 volunteers,” Kamil said at the “Zhifeilongkoma” vaccine clinical trial event held in Bandung on the 3rd. The clinical trials will be conducted in two cities, Jakarta and Bandung. For Bandung City, the number of volunteers required is 2,000.
In another country, Uzbekistan, the Information Bureau of the Ministry of Innovation and Development of Uzbekistan notified on March 1 local time that Uzbekistan has completed the registration of a Chinese Zhifeilongkoma new crown vaccine, and residents of Uzbekistan will be able to get this vaccine. vaccine.
According to local media reports, Zhifeilongkoma vaccine is undergoing phase 3 clinical testing in Uzbekistan. On February 25, an official from the Uzbek Ministry of Innovation and Development stated that the Chinese vaccine, which began clinical testing in Uzbekistan on December 11, 2020, has the two major characteristics of high efficiency and no side effects. There are currently about 7,000 volunteers participating in the test. The results show that the safety of the vaccine is 99% and the effectiveness is 97%.
Mainland China has approved the use of four domestically-made new crown vaccines, including two from Sinopharm and one inactivated vaccine from Kexing. In addition, Cansino’s adenovirus vector vaccine has also been approved. If the Zhifeilongkoma vaccine is approved for marketing in the future, it will be the first “recombinant protein subunit” vaccine approved.
–
And no “recombinant protein subunit” vaccine has been approved in foreign countries. The vaccines currently popular in the Western world are the AstraZeneca adenovirus vector vaccine in the United Kingdom, and the mRNA vaccines of Pfizer (BioNTech) and Modena in the United States.
The “recombinant protein subunit” vaccine is being studied by Novavax in the United States. It announced the interim results of the Phase 3 clinical trial on January 28, and the effective rate reached 89.3%.
The “recombinant protein subunit” vaccine is different from the well-known inactivated vaccines, adenovirus vector vaccines, and mRNA vaccines. The antigen used in the “recombinant protein subunit” vaccine is the modified new coronavirus S protein. This purified protein is encoded by related gene sequences and is produced in insect cells, and then injected into the human body to induce a response from the immune system. The antigens of related vaccines have undergone a lot of recombination to make the S protein more stable.
Zhifei’s “recombinant protein subunit” new crown vaccine is in the final phase of phase 3 clinical trials. Once the clinical trials are over, it can be marketed if approved by the China Food and Drug Administration. According to preliminary estimates, the production capacity of Zhifei’s production workshop can reach 200 to 300 million vaccine doses per year.
– .
